Lyme borreliosis is the most common tick-borne infectious disease in Europe. A neurological manifestation occurs in 3-15% of infections and can manifest as polyradiculitis, meningitis and (rarely) encephalomyelitis. This S3 guideline is directed at physicians in private practices and clinics who treat Lyme neuroborreliosis in children and adults. Twenty AWMF member societies, the Robert Koch Institute, the German Borreliosis Society and three patient organisations participated in its development. A systematic review and assessment of the literature was conducted by the German Cochrane Centre, Freiburg (Cochrane Germany). The main objectives of this guideline are to define the disease and to give recommendations for the confirmation of a clinically suspected diagnosis by laboratory testing, antibiotic therapy, differential diagnostic testing and prevention.
Die Lyme-Borreliose ist die häufigste durch Zecken übertragene Infektionskrankheit in Europa. Eine neurologische Manifestation kommt bei 3–15% der Infektionen vor und kann sich als Polyradikulitis, Meningitis sowie selten als Enzephalomyelitis manifestieren. Die Erkrankung ist durch Antibiotika behandelbar.Diese S3-Leitlinie richtet sich an Ärzte in Praxis und Klinik, die mit der Behandlung der Neuroborreliose bei Kindern und Erwachsenen befasst sind.An der Entwicklung waren 20 AWMF-Mitgliedsgesellschaften, das Robert Koch-Institut, die Deutsche Borreliose-Gesellschaft und 3 Patientenorganisationen beteiligt. Die systematische Literaturrecherche und Literaturbewertung wurden durch das Deutsche Cochrane Zentrum Freiburg (Cochrane Deutschland) durchgeführt.Hauptziele der Leitlinie sind es, die Krankheit zu definieren und Empfehlungen abzugeben zur Bestätigung der Verdachtsdiagnose mittels Laboruntersuchungen, Antibiotikabehandlung, Differenzialdiagnostik und Prävention.

The Arthropod Containment Guidelines are a product of the work of the American Committee of Medical Entomology, a subcommittee of the American Society of Tropical Medicine and Hygiene. The guidelines provide a reference for research laboratories to assess risk and establish protocols for the safe handling of arthropod vectors of human and animal disease agents. The guidelines were originally published in 2004 and have been updated here to reflect the spectrum of vector taxa under investigation, and the demands of working with vector arthropods in the context of the Select Agent Rule.

In response to the global expansion and re-emergence of vector-borne diseases, WHO launched the Global Vector Control Response program in 2017. The aim is to strengthen vector control through increased capacity, innovation, improved surveillance, better coordination, and integrated action. Will this new approach overcome the failings of previous initiatives?

暂无摘要。

暂无摘要。

The natural existence of this vectorial zoonosis and the development since 1991 of initiatives in the American Region in order to control Chagas Disease, did necessary to prepare this document to update the knowledge about the disease and to exhibit guidelines for healthcare workers in Chile, as Chagas disease is a public health problem that needs to be attended in an integral way. A definition for Chagas disease and its classification according to the international classification of diseases (ICD 10) are presented. The general importance and disease load are concise and briefly commented, while the vector geographic distribution, the magnitude in Chile, its reservoir, the parasite main characteristics and its transmission mechanisms are reviewed. A definition for acute suspected and confirmed cases is given, and the epidemiological situation in Chile and a brief cost-benefit analysis of Chagas disease are presented.

暂无摘要。

暂无摘要。